HCI, pH 7 .0, the sample was passed through a column of normal mouse Ig (prepared from Tresyl-Sepharose; Pharmacia Fine Chemicals) . The unbound sample was then applied to a column of mAb KF23-Sepharose (3.5 mg/ml), also prepared from Tresyl-Sepharose. The column was washed with 0.1 M NaCl, 0.01 M Tris-HCI, pH 7.0, and 0.5 M NaCl, 0 .01 M Tris, pH 8.5, and antigen was then eluted with 0.1 M NaCl, 50 mM diethylamine-HCI (pH 11.5). For further purification, the column eluate was dialyzed against water, lyophilized, and separated by SDS-PAGE on a 7% gel . After electrophoresis, the antigen (N10 gg) was transferred to polyvinylidene difluoride membrane (Millipore Continental Water Systems, Bedford, MA) in transfer buffer (10 mM 3-[cyclohexylamino]-1-propanesulfonic acid containing 10% methanol) as described by Matsudaira (9) . The membrane was rinsed in water and air dried and the 90-95-kD region was located using prestained standards in adjacent lanes and cut out. The sample was used for amino acid sequencing using a gas phase sequenator (Applied Biosystems, Inc., Foster City, CA) at the Harvard Microchemistry facility (Boston, MA).
Tryptic Peptide Mapping. Proteins, isolated by antibody affinity chromatography and SDS-PAGE as described above, were radioiodinated with "'I by the chloramine T procedure (10) and further purified by SDS-PAGE. Gel slices containing the antigen were washed successively with 10% acetic acid and 10% methanol. After drying by lyophilization they were placed in a solution of 50 ug/ml of DPCC-trypsin (Sigma Chemical Co., St. Louis, MO) in 0.13 M ammonium bicarbonate . After incubating overnight at 37°C, the trypsin solution was removed, the slices were washed with water, and the combined extracts were lyophilized . The tryptic digests were analyzed by two-dimensional (2D) mapping as described by Elder et al. (I1) and the peptides were detected by autoradiography with XAR-5 film (Kodak) .
Results
Two lines ofevidence demonstrated the relationship between the FD epitope-bearing gp90 and gp95/p97 . Sequential radioimmunoprecipitation experiments showed that preclearing of a 125 I-labeled antigen preparation from the allogeneic melanoma cell line SK-MEL-28 with mAb KF23 (detecting gp90) removed antigen reacting with mAb 112 (detecting gp95) (Fig. 1) . Also, mAb 112 removed all the antigen from SK-MEL-131 reacting with human serum FD (detecting the unique epitope) . Furthermore, we determined the partial NH2-terminal amino acid sequence of purified gp90 glycoprotein from SK-MEL-28 cells. The antigen was isolated from the spent culture medium of SK-MEL-28 cells by con A-agarose and mAb KF23 antibody affinity chromatography, followed by preparative SDS-PAGE. After the affinity chromatography step, the sample contained three components in the 90-kD region (data not shown), which were reduced to one component in 2D IEF SDS-PAGE after neuraminidase treatment (Fig. 2 A) . Immunoprecipitation with mAb KF23 confirmed that this component was gp90. Determination of the partial NH2-terminal amino acid sequence by a gas phase sequenator showed identity to the previously reported sequence for p97 derived either from NH2-terminal amino acid sequencing (12) or deduced from the nucleotide sequence of the cloned gene (13) (Fig. 2 B) . From these data we conclude that gp90 is identical to the previously described gp95 and p97 antigens; in addition, the FD epitope is carried on the gp95/p97 glycoprotein . This molecule has amino acid sequence homology to transferrin and also binds iron and has been termed melanotransferrin (12) .
In an attempt to determine the biochemical basis for the expression of the FD determinant in gp95/p97 from SK-MEL-131 cells, but not SK-MEL-28 cells, tryptic peptide maps of the purified antigens from the two cell lines were compared (Fig.  3) . No reproducible differences were found between the tryptic peptides of the antigen from FD' and FD-cells. 9) showed that the FD determinant is carriedon gp95 . The unidentified components in some of the lanes are nonspecific components . FIGURE 2. Purification and partial amino acid sequence of gp90 . (A) The two-dimensional IEFSDS-PAGE analysis of the sample purified as described in Materials and Methods. The sample was treated with neuraminidase (0 .3 U/ml for 3 h at 37°C) before separation . Gp90 is indicated with an arrow; the other components are albumin, which was later removed by preparative SDS-PAGE, and IEF markers (m). (B) the N terminal amino acid data on the purified protein and the sequence is compared with the published sequence for p97 (12, 13) . 
Discussion
Although gp95/p97 is preferentially expressed on melanoma cell lines, it is found on a range of other cultured cell types (5-7) . In vivo gp95/p97 is expressed strongly in the majority of melanoma tumors but only weakly on epithelial cancers (14, 15) . The expression of gp95/p97 on normal tissues is generally limited to sweat gland ducts and the linings of blood vessels in some tissues (4) . Using double-determinant assays, Brown et al. (16) demonstrated a range of 0.1-610 ng/mg tissue in melanoma tissues and a range of 0 .1-10 ng/mg in normal adult tissues .
The fact that the FD specificity is heat labile and trypsin sensitive suggests that FD is a protein epitope . Both the original gp95/p97 from SK-MEL-131 and SK-MEL-28 cells and neuraminidase-, endo-N-acetylglucosaminidase-, or N-glycanasetreated products had identical molecular sizes as determined by SDS-PAGE (data not shown), indicating that there are no major molecular differences, which would have resulted in differences in mobility, in either the polypeptide or carbohydrate moieties of gp95/p97 from FD' and FD -cell sources . No significant differences were detected in 2D maps of 125 1-labeled tryptic peptides of gp95/p97 from SK-MEL-131 and -28 cells . These results suggest that discrete differences, such as single amino acid substitutions, distinguish the two species . The observation made previ-ously (4) that FD serum only partially removes molecules reacting with KF26 (another mAb detecting gp95/p97) could be explained by the low affinity of FD antibodies, but it also raises the interesting possibility that a mixed population of gp95/p97 molecules, corresponding to common and unique forms, may be produced by SK-MEL-131 .
This demonstration that the autoimmunogenic melanoma epitope FD resides on a common melanoma antigen (gp95/p97) raises a number of interesting questions for tumor immunology. As only a single melanoma cell line in the series tested expressed the FD determinant, the expression of this novel epitope in gp95/p97 is uncommon . However, it focuses attention on the possibility of other changes in gp95/p97 in melanoma, and the available molecular probes for this glycoprotein (13) Received for publication 12 September 1988 and in revised form 1 November 1988.
